7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 
      
    		                                        
      cash flows from operating activities
    		                                        
      net income
    		-53,852,000 -50,469,000 -46,878,000 29,253,000 -61,780,000 -32,923,000 -31,558,000 -16,256,000 7,252,000 -21,104,000 -27,405,000 -43,709,000 -39,004,000 -41,296,000 -37,814,000 -34,785,000 -6,230,000 -38,766,000 -42,464,000 -28,789,000 -33,100,000 -40,528,000 -47,493,000 -56,770,000 -50,726,000 -41,942,000 -44,200,000 -37,887,000 -37,631,000 -35,894,000 -35,241,000 -30,211,000 -26,135,000 -24,693,000 -20,996,000 -18,454,000 -17,535,000 -11,565,000 -7,847,000 -7,099,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                                        
      amortization of right-of-use assets
    		1,374,000 1,331,000 1,289,000 1,249,000 1,210,000 1,173,000 1,135,000 1,101,000 1,067,000 1,033,000 1,005,000 983,000 964,000 809,000 784,000 759,000 550,000 531,000 512,000 493,000 476,000 458,000 442,000 426,000 411,000 395,000 381,000              
      depreciation of property and equipment
    		856,000 865,000 875,000 907,000 948,000 999,000 1,042,000 1,081,000 1,197,000 1,289,000 1,433,000 1,512,000 1,637,000 1,695,000 1,730,000 1,779,000 1,847,000 1,909,000 1,948,000 2,017,000 2,034,000 2,024,000 2,039,000 2,004,000 1,947,000 1,854,000 1,783,000 1,714,000 1,458,000 1,234,000 1,175,000  595,000 356,000 315,000      
      share-based compensation expense
    		6,472,000 6,196,000 4,953,000 3,244,000 3,531,000 3,485,000 2,881,000 2,352,000 2,284,000 2,409,000 2,750,000 2,907,000 3,366,000 6,950,000 3,971,000 3,726,000 5,896,000 2,722,000 4,063,000 3,219,000 3,284,000 3,794,000 3,999,000 4,987,000 5,020,000 5,157,000 4,345,000 4,011,000 3,610,000 3,545,000 4,430,000 3,177,000 3,000,000 2,967,000 2,999,000 2,528,000 2,183,000 1,270,000 866,000 814,000 
      changes in operating assets and liabilities:
    		                                        
      accounts receivable
    		-8,383,000 -1,617,000 1,422,000 -1,422,000 1,290,000 -1,290,000 21,086,000 -14,086,000        22,500,000 -22,500,000   0 0 0 20,000,000 0 0   0 5,000,000           0 
      prepaid expenses
    		47,000 1,362,000 1,482,000 1,028,000 1,575,000 -1,008,000 -1,227,000 -2,398,000 1,498,000 219,000 -1,299,000 -513,000 -2,023,000 1,544,000 -356,000 1,043,000 1,561,000 1,242,000 4,000 -2,468,000 -1,514,000 3,547,000 -373,000                  
      other assets
    		4,847,000 -199,000 118,000 -4,214,000 2,389,000 -6,000 -1,394,000 91,000 272,000 -569,000 -1,804,000 -109,000 5,449,000 -1,095,000 -851,000 -1,385,000 4,522,000 -1,760,000 -1,715,000 -985,000 15,257,000 1,832,000 -1,983,000                  
      accounts payable
    		59,000 276,000 -2,052,000 3,460,000 -5,078,000 6,107,000 -1,068,000 192,000 503,000 218,000 -4,674,000 1,011,000 5,073,000 774,000 2,490,000 -232,000 -1,084,000 -4,785,000 -466,000 4,555,000 -4,200,000 -2,574,000 7,336,000 -10,968,000 8,431,000 -1,743,000 783,000 2,135,000 3,113,000 -702,000 390,000 3,268,000 -1,061,000 668,000 1,017,000 1,470,000 716,000 1,479,000 -296,000 -816,000 
      accrued expenses and other current liabilities
    		3,461,000 5,213,000 -13,268,000 6,939,000 3,465,000 4,056,000 -10,207,000 4,204,000 2,195,000 2,807,000 -9,930,000 6,496,000 -29,000 4,156,000 -7,932,000 3,497,000 1,441,000 3,262,000 -5,310,000 1,789,000 1,962,000 -2,774,000 -5,191,000 2,446,000 2,106,000 3,363,000 -6,467,000 5,217,000 1,416,000 1,772,000 -2,541,000 2,652,000 1,734,000 701,000 -537,000 -188,000 1,276,000 879,000 329,000 340,000 
      deferred revenue
    		2,392,000 -7,082,000 -9,175,000 -82,326,000 7,677,000 -6,402,000 -12,538,000 -7,971,000 -42,042,000 -22,107,000 126,448,000 -1,239,000 -151,000 -271,000 -1,584,000 -1,765,000 -13,923,000   -9,439,000 -3,450,000 -3,027,000 -4,161,000 -2,400,000 -2,929,000 -7,628,000 -3,026,000 -3,622,000 -4,492,000 170,121,000 -1,422,000 -676,000 -676,000 -676,000 -676,000 -677,000 2,109,000   0 
      operating lease liabilities
    		-1,939,000 -1,888,000 -1,805,000 -1,766,000 -1,705,000 -1,659,000 -1,584,000 -1,549,000 -1,493,000 -1,452,000 -1,002,000 -981,000 -928,000 -1,220,000 -1,179,000 -1,156,000 -939,000 -912,000 -880,000 -861,000 -821,000 -796,000 -765,000 -750,000 -712,000 -691,000 -663,000              
      net cash from operating activities
    		-44,666,000 -46,012,000 -63,039,000 -43,648,000 -46,478,000 -27,468,000 -33,432,000 -33,239,000 -34,457,000 -37,257,000 85,522,000 -33,440,000 -25,646,000 -28,822,000 -39,873,000 -7,033,000 -28,184,000 -9,401,000 -44,375,000 -31,415,000 -20,172,000 -38,145,000 -26,250,000 -61,240,000 -43,681,000 -32,929,000 -50,381,000 -32,820,000 -29,010,000 71,394,000 -32,426,000 -22,754,000 -23,411,000 -20,088,000 -17,418,000 -13,294,000 -11,832,000 390,000 -7,136,000 -6,668,000 
      capex
    		-248,000 -306,000 -165,000 -86,000 -383,000 -52,000 -417,000 -356,000 -198,000 -72,000 -489,000 -204,000 -457,000 -492,000 -208,000 -15,000 -98,000 -339,000 -108,000 -557,000 -65,000 -136,000 -580,000 0 -465,000 -1,599,000 -508,000 0 -3,389,000 -1,922,000 -1,164,000 -4,079,000 -5,606,000 -5,567,000 -3,635,000 -2,729,000 -1,275,000 0 -685,000 -970,000 
      free cash flows
    		-44,914,000 -46,318,000 -63,204,000 -43,734,000 -46,861,000 -27,520,000 -33,849,000 -33,595,000 -34,655,000 -37,329,000 85,033,000 -33,644,000 -26,103,000 -29,314,000 -40,081,000 -7,048,000 -28,282,000 -9,740,000 -44,483,000 -31,972,000 -20,237,000 -38,281,000 -26,830,000 -61,240,000 -44,146,000 -34,528,000 -50,889,000 -32,820,000 -32,399,000 69,472,000 -33,590,000 -26,833,000 -29,017,000 -25,655,000 -21,053,000 -16,023,000 -13,107,000 390,000 -7,821,000 -7,638,000 
      cash flows from investing activities
    		                                        
      purchases of property and equipment
    		-248,000 -306,000 -165,000 -86,000 -383,000 -52,000 -417,000 -356,000 -198,000 -72,000 -489,000 -204,000 -457,000 -492,000 -208,000 -15,000 -98,000 -339,000 -108,000 -557,000 -65,000 -136,000 -580,000  -465,000 -1,599,000 -508,000  -3,389,000 -1,922,000 -1,164,000 -4,079,000 -5,606,000 -5,567,000 -3,635,000 -2,729,000 -1,275,000    
      net cash from investing activities
    		-248,000 -306,000 -165,000 -86,000 -383,000 -52,000 -417,000 -356,000 -198,000 -72,000 -489,000 24,840,000 -501,000 24,614,000 -50,208,000 -15,000 -98,000 -339,000 -108,000 -557,000 -65,000 -136,000 -580,000 -1,346,000 -465,000 -1,599,000 -508,000 -3,463,000 -3,389,000 -1,922,000 -1,164,000 -4,081,000 -5,608,000 -5,569,000 -3,638,000 -5,328,000 -1,275,000 -874,000 -685,000 -970,000 
      cash flows from financing activities
    		                                        
      proceeds from the issuance of ordinary shares, net of offering costs
    		     0 14,038,000                                  
      proceeds from the issuance of pre-funded warrants, net of offering costs
    		                                        
      proceeds from issuance of ordinary shares pursuant to the “at-the-market” equity program, net of offering costs
    		30,212,000 11,099,000 1,262,000                                      
      proceeds from the exercise of share options
    		2,041,000 594,000 2,451,000 2,060,000 690,000 106,000 123,000 388,000 35,000 85,000 1,000 136,000 50,000 0 37,000 0 50,000 0 200,000 19,000 702,000 10,000 10,000 757,000 253,000 116,000 1,481,000 646,000 1,351,000 1,560,000 1,553,000 604,000 80,000 37,000 206,000 97,000     
      proceeds from the espp
    		439,000 0 442,000 0 310,000 0 349,000 0 319,000 0 429,000 0 198,000 0 174,000                          
      net cash from financing activities
    		32,692,000 11,693,000 4,155,000 34,981,000 203,746,000 653,000 14,510,000 93,962,000 1,670,000 1,849,000 35,053,000 55,000 17,000 65,800,000 1,316,000 33,793,000 8,349,000 5,045,000 8,641,000 19,000 142,523,000 11,382,000 614,000 757,000 253,000 -157,000 163,546,000 646,000 1,351,000 61,560,000 1,537,000 589,000 59,000 93,536,000 190,000 15,000 184,000 28,938,000 -16,000 102,736,000 
      effect of foreign exchange rates on cash, cash equivalents, and restricted cash
    		-29,000 43,000 58,000  120,000 -81,000 -74,000                                  
      net increase in cash, cash equivalents, and restricted cash
    		    157,005,000 -26,948,000 -19,413,000                                  
      cash, cash equivalents, and restricted cash, beginning of period
    		0 0 305,838,000  0 0 204,050,000                                  
      cash, cash equivalents, and restricted cash, end of period
    		-12,251,000 -34,582,000 246,847,000  157,005,000 -26,948,000 184,637,000                                  
      net decrease in cash, cash equivalents, and restricted cash
    		 -34,582,000 -58,991,000                                      
      loss on disposal of property and equipment
    		                             41,000 13,000          
      other non-current liabilities
    		       0       868,000 -1,014,000 675,000 -68,000 -67,000 -946,000 -100,000 -101,000 -100,000 -72,000 -104,000 -142,000 -103,000 647,000 -38,000 -72,000 -14,000 598,000 -1,049,000 15,000 1,259,000 877,000 -4,000 -4,000 -5,000  
      proceeds from the sale of property and equipment
    		           0 0                       0 0    
      purchase of short-term investments
    		           0 -25,044,000 0 -50,000,000                          
      proceeds from the maturity of short-term investments
    		           25,044,000 25,000,000                            
      proceeds from the issuance of ordinary shares as a part of the june 2022 offering, net of offering costs
    		                                        
      proceeds from the issuance of ordinary shares as a part of the december 2023 offering, net of offering costs
    		   0                                     
      proceeds from the issuance of ordinary shares as a part of the september 2024 offering, net of offering costs
    		   27,858,000                                     
      proceeds from issuance pre-funded warrants as a part of the june 2022 offering, net of offering costs
    		                                        
      proceeds from issuance pre-funded warrants as a part of the, september 2024 offering, net of offering costs
    		                                        
      proceeds from issuance of ordinary shares pursuant to the gsk collaboration agreement
    		                                        
      proceeds from issuance of ordinary shares pursuant to the at-the-market equity program
    		              1,105,000 33,793,000 8,027,000 5,045,000 8,105,000 0 47,906,000 11,372,000 604,000                  
      effect of foreign exchange rates on cash
    		                               285,000 30,000 31,000 57,000 -115,000 173,000 -86,000 14,000 82,000 
      net increase in cash, cash equivalents and restricted cash
    		       60,425,000 -33,017,000 -35,580,000 120,065,000     26,668,000    -31,865,000 122,309,000 -26,894,000 -26,210,000 -61,844,000 -43,891,000 -34,655,000 112,754,000 -35,665,000 -30,938,000            
      cash, cash equivalents and restricted cash, beginning of period
    		       0 0 0 92,157,000 0 0 0 154,215,000 0 0 0 188,148,000 0 0 0 150,808,000 0 0 0 178,444,000 0 0 0 146,113,000          
      cash, cash equivalents and restricted cash, end of period
    		       60,425,000 -33,017,000 -35,580,000 212,222,000 -8,451,000 -26,206,000 61,450,000 65,364,000 26,668,000 -19,944,000 -4,695,000 152,186,000 -31,865,000 122,309,000 -26,894,000 124,598,000 -61,844,000 -43,891,000 -34,655,000 291,198,000 -35,665,000 -30,938,000 130,944,000 114,103,000          
      supplemental disclosure of cash flow information:
    		                                        
      offering costs in accounts payable at period end
    		                                        
      increase in operating lease right-of-use assets and lease liabilities related to new lease
    		                                        
      proceeds from the issuance of pre-funded warrants as a part of the september 2024 offering, net of offering costs
    		                                        
      proceeds from the issuance of ordinary shares pursuant to the gsk collaboration agreement
    		                                        
      proceeds from issuance of ordinary share pursuant to the “at-the-market” equity program, net of offering costs
    		                                        
      supplemental disclosure of cash flow information
    		                                        
      offering costs related to the september 2024 offering in accrued expenses at period end
    		                                        
      proceeds from issuance of ordinary share pursuant to the at-the-market equity program, net of offering costs
    		                                        
      proceeds from issuance of ordinary shares, net of offering costs
    		       58,951,000 0   -15,000 -229,000       0    0 0 -273,000 162,065,000 0 0   0 -5,000   0    0 
      proceeds from issuance pre-funded warrants, net of offering costs
    		           -4,000 -64,000                            
      proceeds from the sale property and equipment
    		                                        
      proceeds from maturity of short-term investments
    		                                        
      proceeds from issuance of pre-funded warrants, net of offering costs
    		                                        
      proceeds from issuance of ordinary shares pursuant to the at-the-market equity program, net of offering costs
    		        1,316,000    62,000                            
      effect of foreign exchange rates on cash, cash equivalents and restricted cash
    		        -32,000 -100,000 -21,000  -76,000 -142,000 -86,000  -11,000 0 -120,000  23,000 5,000 6,000  2,000 30,000 97,000  110,000 -88,000 43,000          
      increase in operating lease right-of-use assets and lease liabilities related to lease extension
    		            0                            
      proceeds from issuance of ordinary shares
    		          34,623,000                              
      net decrease in cash, cash equivalents and restricted cash
    		           -8,451,000 -26,206,000 61,450,000 -88,851,000   -4,695,000 -35,962,000            -32,010,000          
      at-the-market offering costs in accounts payable at period end
    		                 -20,000 77,000                      
      proceeds from the employee share purchase plan
    		                272,000 0 336,000                      
      proceeds from the employee share purchase program
    		                   0                     
      deferred follow-on offering costs in accounts payable and accrued expenses at period end
    		                          280,000              
      amortization of lease incentive obligation
    		                           -289,000 -232,000 -162,000 -107,000 -77,000 -65,000 -49,000 -17,000      
      net income on disposal of property and equipment
    		                                        
      deferred rent
    		                           73,000 230,000 283,000 387,000 387,000 1,023,000 1,153,000 1,031,000 194,000 117,000 118,000 136,000 92,000 
      deferred income taxes
    		                               0    -742,000 135,000 48,000 -5,000 -146,000 
      purchases of property and equipment, net of tenant improvement allowances
    		                                        
      payments on capital lease obligation
    		                           0 0 0 -16,000 -15,000 -16,000 -15,000 -16,000 -15,000 -16,000 -15,000 -16,000 -14,000 
      prepaid expenses and other current assets
    		                        -4,564,000 779,000 -637,000 -4,782,000 -1,429,000 -4,773,000 515,000 -2,615,000 -1,544,000 -530,000 -1,813,000 -871,000 1,603,000 -1,655,000 -414,000 -23,000 
      other non-current assets
    		                        -2,561,000 -2,331,000 -2,577,000  -5,000 1,000 -11,000 -351,000       -53,000  
      net (gain) loss on disposal of property and equipment
    		                           0             
      tax benefit related to share-based compensation
    		                                   -243,000     
      costs associated with initial public offering
    		                                   0     
      cash paid for taxes, net of refunds
    		                            16,000 108,000 314,000          
      property and equipment purchases in accounts payable and accrued expenses at period end
    		                            1,298,000 86,000 469,000 -1,080,000 -1,568,000 11,000 2,976,000 58,000     
      tenant improvements paid for by the landlord during the period
    		                            1,499,000 433,000 800,000 0         
      tenant improvements to be reimbursed by the landlord
    		                            628,000 2,395,000 1,279,000          
      adjustments to reconcile net income to net cash flows used in operating activities:
    		                                        
      depreciation and amortization
    		                                   259,000 188,000 184,000 153,000 132,000 
      increase in restricted cash
    		                               -2,000 -2,000 -2,000 -3,000     0 
      proceeds from government grant reimbursements for property and equipment
    		                                       0 
      proceeds from initial public offering, net of offering costs and underwriter commissions
    		                                        
      proceeds from issuance of series b preferred shares, net of offering costs
    		                                       -111,000 
      proceeds from government grant
    		                                       0 
      net increase in cash and cash equivalents
    		                               -25,961,000 -28,930,000 67,910,000 -20,809,000 -18,722,000     
      cash and cash equivalents at beginning of period
    		                               0 0 0 150,293,000 0     
      cash and cash equivalents at end of period
    		                               -25,961,000 -28,930,000 67,910,000 129,484,000 -18,722,000     
      deferred offering costs in accounts payable and accrued expenses at period end
    		                                        
      cash paid for interest
    		                                        
      equipment acquired for capital lease obligation
    		                                        
      deferred follow-on offering costs in accrued expenses at period end
    		                                        
      increase in the lease incentive obligation during the period
    		                                  1,082,000      
      conversion of related party notes payable into ordinary and series a preferred shares
    		                                        
      reclassification of series a preferred shares from permanent equity to temporary equity
    		                                        
      increase in accounts payable for initial public offering costs
    		                                        
      payments associated with initial public offering
    		                                        
      proceeds from the exercise of stock options
    		                                        
      net increase in cash
    		                                     28,368,000 -7,823,000 95,180,000 
      cash at beginning of period
    		                                     0 161,220,000 0 
      cash at end of period
    		                                     28,368,000 153,397,000 95,180,000 
      property and equipment purchases in accounts payable at period end
    		                                     854,000 185,000  
      •
    		                                        
      purchase of property and equipment
    		                                      -685,000 -970,000 
      outstanding as of january 1, 2016
    		                                      2,215,342,000  
      granted
    		                                      317,000,000  
      cancelled or forfeited
    		                                      -1,616,000  
      outstanding as of march 31, 2016
    		                                      2,530,726,000  
      options exercisable as of march 31, 2016
    		                                      848,223,000  
      options vested and expected to vest as of march 31, 2016
    		                                      2,434,625,000  
      proceeds from sale of property and equipment
    		                                        
      proceeds from related party notes payable
    		                                        
      payment of related party notes payable
    		                                        
      equipment under acquired for capital lease obligation
    		                                        
      conversion of ordinary shares into series a preferred shares
    		                                        
      property and equipment purchases in accounts payable
    		                                        
      increase in accrued expenses for deferred offering costs
    		                                        
      furniture and equipment
    		                                       -2,859,000 
      leasehold improvements
    		                                        
      total
    		                                        
      less accumulated depreciation and amortization
    		                                        
      property and equipment
    		                                        
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.